<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on September 20, 2023</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/ct2/show/NCT03784417</url>
  </required_header>
  <id_info>
    <org_study_id>EUS-LASER</org_study_id>
    <nct_id>NCT03784417</nct_id>
  </id_info>
  <brief_title>EUS-guided Laser Ablation in Pancreatic Adenocarcinoma</brief_title>
  <official_title>EUS-guided Laser Complete Ablation of Advanced Pancreatic Ductal Adenocarcinoma: a Feasibility Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Catholic University of the Sacred Heart</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Catholic University of the Sacred Heart</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study evaluates the possibility of performing local therapy for PDAC using laser&#xD;
      ablation of the tumor under ultrasonography (EUS) guidance.&#xD;
&#xD;
      Safety of the procedure as well as post procedural quality of life will be also evaluated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Pancreatic adenocarcinoma (PDAC) is projected to be the second cause of cancer death in&#xD;
      Western societies within a decade. Management include chemotherapy and/or radiation therapy,&#xD;
      while resectable disease is possible only in 15% of cases.&#xD;
&#xD;
      Despite these therapeutic approaches, the survival rate of unresectable pancreatic cancer&#xD;
      remains disappointing. Recently, there is a growing interest in the development of&#xD;
      alternative therapeutic approaches, which can work in parallel with standard chemoradiation&#xD;
      therapy. These methods include intra-lesion injection/instillation of antitumoral agents&#xD;
      performed through a laparoscopic approach, or percutaneously or under endoscopic ultrasound&#xD;
      (EUS) guidance and tumor volume reduction procedures using ablative techniques.&#xD;
&#xD;
      In this context laser ablation has been reported to be effective in inducing coagulative&#xD;
      necrosis of the tumour in absence of major adverse events. However, the available studies on&#xD;
      the matter are limited by small sample size, lack of extended follow up and informations&#xD;
      about the possibility to ablate the entire tumour mass.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Terminated</overall_status>
  <why_stopped>
    device unavalaible&#xD;
  </why_stopped>
  <start_date type="Actual">October 15, 2019</start_date>
  <completion_date type="Actual">December 15, 2021</completion_date>
  <primary_completion_date type="Actual">December 15, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor</measure>
    <time_frame>at 1 month from the intervention</time_frame>
    <description>Number of patients with necrosis of the tumor, as demonstrated by the involution of the pancreatic mass on CT scan performed after one month from the treatment</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Incidence of early and late adverse events after EUS-guided laser ablation (LA)</measure>
    <time_frame>at 7 days and 3 months from the intervention</time_frame>
    <description>Percentage of early and late adverse events. Early adverse events will be those occurring during the procedure up to the first week after the ablation treatment. Late adverse events will be defined as any adverse event potentially related to the procedure occurring at the site of the primary tumor within 3 months after EUS LA treatment. Adverse events will be considered major if they prevent completion of the scheduled procedure and/or resulted in prolongation of hospital stay, another therapeutic procedure (needing sedation/anesthesia), or subsequent medical consultation. Any potential adverse event such as pancreatitis, burns of the gastric or duodenal walls, bowel injury, or peritonitis will be recorded and graded according to the above-mentioned classification.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Disease response to EUS-guided laser ablation (LA)</measure>
    <time_frame>From date of treatment, every 4 months, assessed until death or up to 2 years</time_frame>
    <description>Correlation between RNA markers evaluated by TaqMan RNA assay in serum and treatment response</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Post-procedural quality of life</measure>
    <time_frame>From date of enrollment (baseline), every 2 months, assessed until death or up to 2 years</time_frame>
    <description>Change from baseline in quality of life (QOL) scores after treatment evaluated by using the European Organization for Research and Treatment core quality of life questionnaire (EORTC QLQ-C30), version 3.0. EORTC QLQ-C30 questionnaire evaluates 5 functions physical,role,cognitive, emotional, and social), 9 symptoms (fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties) and the global health status. Questions regarding functions and symptoms are scored 1 to 4, with higher values representing a worse outcomes. Questions regarding global health status are scored 1 to 7, with higher values representing better outcomes.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Progression-free-survival (PFS)</measure>
    <time_frame>From date of enrollment assessed until death or up to 2 years</time_frame>
    <description>PFS defined as the time from the date of trial entry until disease progression or relapse.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>From date of enrollment assessed until death or up to 2 years</time_frame>
    <description>Overall survival defined as the length of time (in days) between the treatment date and the date of death.</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Actual">5</enrollment>
  <condition>Pancreatic Adenocarcinoma</condition>
  <condition>Pancreas Cancer</condition>
  <arm_group>
    <arm_group_label>EUS-guided laser ablation</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>EUS-guided laser ablation</intervention_name>
    <description>EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.</description>
    <arm_group_label>EUS-guided laser ablation</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Histological diagnosis of pancreatic ductal adenocarcinoma&#xD;
&#xD;
          -  Unresectable advanced, non-metastatic Stage III tumor&#xD;
&#xD;
          -  Stable disease without regression or progression after 6 months of chemotherapeutic&#xD;
             treatment&#xD;
&#xD;
          -  Locally progressive disease after chemiotherapy, without evidence of metastases&#xD;
&#xD;
          -  Age &gt;18 and &lt;80 years&#xD;
&#xD;
          -  Willing to be followed up c/o the Fondazione Policlinico A. Gemelli University&#xD;
             Hospital&#xD;
&#xD;
          -  Signed informed consent&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Stage I, Stage II, Stage IV disease&#xD;
&#xD;
          -  Absolute contraindications to general anesthesia or deep sedation&#xD;
&#xD;
          -  Absolute contraindications to perform digestive endoscopy&#xD;
&#xD;
          -  Known bleeding disorder that cannot be sufficiently corrected with co-fact or fresh&#xD;
             frozen plasma (FFP)&#xD;
&#xD;
          -  Use of anticoagulants that cannot be discontinued&#xD;
&#xD;
          -  International Normalized Ratio (INR) &gt;1.5 or platelet count &lt;50.000&#xD;
&#xD;
          -  Pregnancy or lactation&#xD;
&#xD;
          -  Unable to sigh informed consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Alberto Larghi, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Fondazione Policlinico Universitario Agostino Gemelli</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Fondazione Policlinico Universitario Agostino Gemelli</name>
      <address>
        <city>Roma</city>
        <state>RM</state>
        <zip>00168</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Universita' Cattolica del Sacro Cuore</name>
      <address>
        <city>Rome</city>
        <zip>00136</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <reference>
    <citation>Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018 Apr 1;47(2):427-439. doi: 10.1093/ije/dyx232.</citation>
    <PMID>29149259</PMID>
  </reference>
  <reference>
    <citation>Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Nov 27;371(22):2140-1. doi: 10.1056/NEJMc1412266. No abstract available.</citation>
    <PMID>25427123</PMID>
  </reference>
  <reference>
    <citation>Lakhtakia S, Seo DW. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc. 2017 May;29(4):486-494. doi: 10.1111/den.12833. Epub 2017 Mar 16.</citation>
    <PMID>28171697</PMID>
  </reference>
  <reference>
    <citation>Han J, Chang KJ. Endoscopic Ultrasound-Guided Direct Intervention for Solid Pancreatic Tumors. Clin Endosc. 2017 Mar;50(2):126-137. doi: 10.5946/ce.2017.034. Epub 2017 Mar 30.</citation>
    <PMID>28391669</PMID>
  </reference>
  <reference>
    <citation>Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010 Feb;97(2):220-5. doi: 10.1002/bjs.6800.</citation>
    <PMID>20069610</PMID>
  </reference>
  <reference>
    <citation>Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, Salvia R, Bassi C. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013 Jan;398(1):63-9. doi: 10.1007/s00423-012-1011-z. Epub 2012 Sep 29.</citation>
    <PMID>23053459</PMID>
  </reference>
  <reference>
    <citation>Kim HJ, Seo DW, Hassanuddin A, Kim SH, Chae HJ, Jang JW, Park DH, Lee SS, Lee SK, Kim MH. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc. 2012 Nov;76(5):1039-43. doi: 10.1016/j.gie.2012.07.015.</citation>
    <PMID>23078928</PMID>
  </reference>
  <reference>
    <citation>Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location. AJR Am J Roentgenol. 2012 Dec;199(6):1393-401. doi: 10.2214/AJR.11.7850.</citation>
    <PMID>23169736</PMID>
  </reference>
  <reference>
    <citation>Di Matteo F, Martino M, Rea R, Pandolfi M, Rabitti C, Masselli GM, Silvestri S, Pacella CM, Papini E, Panzera F, Valeri S, Coppola R, Costamagna G. EUS-guided Nd:YAG laser ablation of normal pancreatic tissue: a pilot study in a pig model. Gastrointest Endosc. 2010 Aug;72(2):358-63. doi: 10.1016/j.gie.2010.02.027. Epub 2010 Jun 11.</citation>
    <PMID>20541187</PMID>
  </reference>
  <reference>
    <citation>Carrara S, Arcidiacono PG, Albarello L, Addis A, Enderle MD, Boemo C, Campagnol M, Ambrosi A, Doglioni C, Testoni PA. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. Endoscopy. 2008 Apr;40(4):321-6. doi: 10.1055/s-2007-995595.</citation>
    <PMID>18389449</PMID>
  </reference>
  <reference>
    <citation>Di Matteo FM, Saccomandi P, Martino M, Pandolfi M, Pizzicannella M, Balassone V, Schena E, Pacella CM, Silvestri S, Costamagna G. Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. Gastrointest Endosc. 2018 Jul;88(1):168-174.e1. doi: 10.1016/j.gie.2018.02.007. Epub 2018 Feb 13.</citation>
    <PMID>29452076</PMID>
  </reference>
  <reference>
    <citation>Di Matteo F, Picconi F, Martino M, Pandolfi M, Pacella CM, Schena E, Costamagna G. Endoscopic ultrasound-guided Nd:YAG laser ablation of recurrent pancreatic neuroendocrine tumor: a promising revolution? Endoscopy. 2014;46 Suppl 1 UCTN:E380-1. doi: 10.1055/s-0034-1377376. Epub 2014 Sep 25. No abstract available.</citation>
    <PMID>25254586</PMID>
  </reference>
  <reference>
    <citation>Gress TM, Lausser L, Schirra LR, Ortmuller L, Diels R, Kong B, Michalski CW, Hackert T, Strobel O, Giese NA, Schenk M, Lawlor RT, Scarpa A, Kestler HA, Buchholz M. Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material. Oncotarget. 2017 Nov 21;8(64):108223-108237. doi: 10.18632/oncotarget.22601. eCollection 2017 Dec 8.</citation>
    <PMID>29296236</PMID>
  </reference>
  <reference>
    <citation>Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.</citation>
    <PMID>8433390</PMID>
  </reference>
  <verification_date>February 2022</verification_date>
  <study_first_submitted>November 25, 2018</study_first_submitted>
  <study_first_submitted_qc>December 20, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">December 21, 2018</study_first_posted>
  <last_update_submitted>February 10, 2022</last_update_submitted>
  <last_update_submitted_qc>February 10, 2022</last_update_submitted_qc>
  <last_update_posted type="Actual">February 28, 2022</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Catholic University of the Sacred Heart</investigator_affiliation>
    <investigator_full_name>Guido Costamagna</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenocarcinoma</mesh_term>
    <mesh_term>Pancreatic Neoplasms</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>


download date: ClinicalTrials.gov processed this data on September 20, 2023
link text: Link to the current ClinicalTrials.gov record.
url: https://clinicaltrials.gov/ct2/show/NCT03784417
org study id: EUS-LASER
nct id: NCT03784417
lead sponsor: 
is fda regulated drug: No
is fda regulated device: No
This study evaluates the possibility of performing local therapy for PDAC using laser
      ablation of the tumor under ultrasonography (EUS) guidance.

      Safety of the procedure as well as post procedural quality of life will be also evaluated.
Pancreatic adenocarcinoma (PDAC) is projected to be the second cause of cancer death in
      Western societies within a decade. Management include chemotherapy and/or radiation therapy,
      while resectable disease is possible only in 15% of cases.

      Despite these therapeutic approaches, the survival rate of unresectable pancreatic cancer
      remains disappointing. Recently, there is a growing interest in the development of
      alternative therapeutic approaches, which can work in parallel with standard chemoradiation
      therapy. These methods include intra-lesion injection/instillation of antitumoral agents
      performed through a laparoscopic approach, or percutaneously or under endoscopic ultrasound
      (EUS) guidance and tumor volume reduction procedures using ablative techniques.

      In this context laser ablation has been reported to be effective in inducing coagulative
      necrosis of the tumour in absence of major adverse events. However, the available studies on
      the matter are limited by small sample size, lack of extended follow up and informations
      about the possibility to ablate the entire tumour mass.
allocation: N/A
intervention model: Single Group Assignment
primary purpose: Treatment
masking: None (Open Label)
measure: Tumor necrosis induction by EUS-guided laser ablation (LA) - Number of patients with necrosis of the tumor
time frame: at 1 month from the intervention
description: Number of patients with necrosis of the tumor, as demonstrated by the involution of the pancreatic mass on CT scan performed after one month from the treatment
measure: Incidence of early and late adverse events after EUS-guided laser ablation (LA)
time frame: at 7 days and 3 months from the intervention
description: Percentage of early and late adverse events. Early adverse events will be those occurring during the procedure up to the first week after the ablation treatment. Late adverse events will be defined as any adverse event potentially related to the procedure occurring at the site of the primary tumor within 3 months after EUS LA treatment. Adverse events will be considered major if they prevent completion of the scheduled procedure and/or resulted in prolongation of hospital stay, another therapeutic procedure (needing sedation/anesthesia), or subsequent medical consultation. Any potential adverse event such as pancreatitis, burns of the gastric or duodenal walls, bowel injury, or peritonitis will be recorded and graded according to the above-mentioned classification.
measure: Disease response to EUS-guided laser ablation (LA)
time frame: From date of treatment, every 4 months, assessed until death or up to 2 years
description: Correlation between RNA markers evaluated by TaqMan RNA assay in serum and treatment response
measure: Post-procedural quality of life
time frame: From date of enrollment (baseline), every 2 months, assessed until death or up to 2 years
description: Change from baseline in quality of life (QOL) scores after treatment evaluated by using the European Organization for Research and Treatment core quality of life questionnaire (EORTC QLQ-C30), version 3.0. EORTC QLQ-C30 questionnaire evaluates 5 functions physical,role,cognitive, emotional, and social), 9 symptoms (fatigue, pain, nausea and vomiting, dyspnea, loss of appetite, insomnia, constipation, diarrhea, and financial difficulties) and the global health status. Questions regarding functions and symptoms are scored 1 to 4, with higher values representing a worse outcomes. Questions regarding global health status are scored 1 to 7, with higher values representing better outcomes.
measure: Progression-free-survival (PFS)
time frame: From date of enrollment assessed until death or up to 2 years
description: PFS defined as the time from the date of trial entry until disease progression or relapse.
measure: Overall survival
time frame: From date of enrollment assessed until death or up to 2 years
description: Overall survival defined as the length of time (in days) between the treatment date and the date of death.
arm group label: EUS-guided laser ablation
arm group type: Experimental
description: Laser ablation will be performed using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge needle under endoscopic ultrasonography guidance.
intervention type: Device
intervention name: EUS-guided laser ablation
description: EUS-guided LA will be performed with an endoscopic ultrasound guided approach using a 1064-nm wavelength laser with the insertion of a 300-μm optical fiber through a 22-gauge flexible needle that is inserted in the working channel of the echoendoscope.
arm group label: EUS-guided laser ablation
criteria: 
gender: All
minimum age: 18 Years
maximum age: 80 Years
healthy volunteers: No
last name: Alberto Larghi, PhD
role: Principal Investigator
affiliation: Fondazione Policlinico Universitario Agostino Gemelli
facility: 
facility: 
country: Italy
citation: Gordon-Dseagu VL, Devesa SS, Goggins M, Stolzenberg-Solomon R. Pancreatic cancer incidence trends: evidence from the Surveillance, Epidemiology and End Results (SEER) population-based data. Int J Epidemiol. 2018 Apr 1;47(2):427-439. doi: 10.1093/ije/dyx232.
PMID: 29149259
citation: Ryan DP, Hong TS, Bardeesy N. Pancreatic adenocarcinoma. N Engl J Med. 2014 Nov 27;371(22):2140-1. doi: 10.1056/NEJMc1412266. No abstract available.
PMID: 25427123
citation: Lakhtakia S, Seo DW. Endoscopic ultrasonography-guided tumor ablation. Dig Endosc. 2017 May;29(4):486-494. doi: 10.1111/den.12833. Epub 2017 Mar 16.
PMID: 28171697
citation: Han J, Chang KJ. Endoscopic Ultrasound-Guided Direct Intervention for Solid Pancreatic Tumors. Clin Endosc. 2017 Mar;50(2):126-137. doi: 10.5946/ce.2017.034. Epub 2017 Mar 30.
PMID: 28391669
citation: Girelli R, Frigerio I, Salvia R, Barbi E, Tinazzi Martini P, Bassi C. Feasibility and safety of radiofrequency ablation for locally advanced pancreatic cancer. Br J Surg. 2010 Feb;97(2):220-5. doi: 10.1002/bjs.6800.
PMID: 20069610
citation: Girelli R, Frigerio I, Giardino A, Regi P, Gobbo S, Malleo G, Salvia R, Bassi C. Results of 100 pancreatic radiofrequency ablations in the context of a multimodal strategy for stage III ductal adenocarcinoma. Langenbecks Arch Surg. 2013 Jan;398(1):63-9. doi: 10.1007/s00423-012-1011-z. Epub 2012 Sep 29.
PMID: 23053459
citation: Kim HJ, Seo DW, Hassanuddin A, Kim SH, Chae HJ, Jang JW, Park DH, Lee SS, Lee SK, Kim MH. EUS-guided radiofrequency ablation of the porcine pancreas. Gastrointest Endosc. 2012 Nov;76(5):1039-43. doi: 10.1016/j.gie.2012.07.015.
PMID: 23078928
citation: Francica G, Petrolati A, Di Stasio E, Pacella S, Stasi R, Pacella CM. Effectiveness, safety, and local progression after percutaneous laser ablation for hepatocellular carcinoma nodules up to 4 cm are not affected by tumor location. AJR Am J Roentgenol. 2012 Dec;199(6):1393-401. doi: 10.2214/AJR.11.7850.
PMID: 23169736
citation: Di Matteo F, Martino M, Rea R, Pandolfi M, Rabitti C, Masselli GM, Silvestri S, Pacella CM, Papini E, Panzera F, Valeri S, Coppola R, Costamagna G. EUS-guided Nd:YAG laser ablation of normal pancreatic tissue: a pilot study in a pig model. Gastrointest Endosc. 2010 Aug;72(2):358-63. doi: 10.1016/j.gie.2010.02.027. Epub 2010 Jun 11.
PMID: 20541187
citation: Carrara S, Arcidiacono PG, Albarello L, Addis A, Enderle MD, Boemo C, Campagnol M, Ambrosi A, Doglioni C, Testoni PA. Endoscopic ultrasound-guided application of a new hybrid cryotherm probe in porcine pancreas: a preliminary study. Endoscopy. 2008 Apr;40(4):321-6. doi: 10.1055/s-2007-995595.
PMID: 18389449
citation: Di Matteo FM, Saccomandi P, Martino M, Pandolfi M, Pizzicannella M, Balassone V, Schena E, Pacella CM, Silvestri S, Costamagna G. Feasibility of EUS-guided Nd:YAG laser ablation of unresectable pancreatic adenocarcinoma. Gastrointest Endosc. 2018 Jul;88(1):168-174.e1. doi: 10.1016/j.gie.2018.02.007. Epub 2018 Feb 13.
PMID: 29452076
citation: Di Matteo F, Picconi F, Martino M, Pandolfi M, Pacella CM, Schena E, Costamagna G. Endoscopic ultrasound-guided Nd:YAG laser ablation of recurrent pancreatic neuroendocrine tumor: a promising revolution? Endoscopy. 2014;46 Suppl 1 UCTN:E380-1. doi: 10.1055/s-0034-1377376. Epub 2014 Sep 25. No abstract available.
PMID: 25254586
citation: Gress TM, Lausser L, Schirra LR, Ortmuller L, Diels R, Kong B, Michalski CW, Hackert T, Strobel O, Giese NA, Schenk M, Lawlor RT, Scarpa A, Kestler HA, Buchholz M. Combined microRNA and mRNA microfluidic TaqMan array cards for the diagnosis of malignancy of multiple types of pancreatico-biliary tumors in fine-needle aspiration material. Oncotarget. 2017 Nov 21;8(64):108223-108237. doi: 10.18632/oncotarget.22601. eCollection 2017 Dec 8.
PMID: 29296236
citation: Aaronson NK, Ahmedzai S, Bergman B, Bullinger M, Cull A, Duez NJ, Filiberti A, Flechtner H, Fleishman SB, de Haes JC, et al. The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst. 1993 Mar 3;85(5):365-76. doi: 10.1093/jnci/85.5.365.
PMID: 8433390
responsible party type: Principal Investigator
investigator affiliation: Catholic University of the Sacred Heart
investigator full name: Guido Costamagna
investigator title: Professor
mesh term: Adenocarcinoma
mesh term: Pancreatic Neoplasms
sharing ipd: No